Fennec Pharmaceuticals Inc.
TSX:FRX.TOBiotechnology
Healthcare
$19.17 -1.71%
-$0.22 today
- Market cap
- $676.80M
- Beta
- 1.08
- P/E (TTM)
- -36.5
- EPS (TTM)
- -$0.24
52W Low $7.59High $14.24
Volume 0.00M
Average 0.00M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$14.67M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$25.01M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.35M) | (23.71M) | (16.05M) | (436K) | (9.74M) |
| Depreciation & Amortization | 0 | 0 | 0 | 800K | 103K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.02M | 4.22M | 5.35M | 5.06M | 7.03M |
| Change in Working Capital | (932K) | 1.1M | (6.78M) | 16.94M | (12.04M) |
| Accounts Receivables | 0 | (1.55M) | (7.27M) | (7.87M) | (12.44M) |
| Inventory | 0 | (576K) | (1.58M) | 579K | (1.28M) |
| Accounts Payables | (794K) | 1.61M | 1.39M | (537K) | 1.39M |
| Other Working Capital | (138K) | 1.61M | 683K | 24.77M | 282K |
| Other Non-Cash Items | 307K | 466K | 326K | 4.61M | (26.45K) |
| Operating Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (14.67M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 5M | 19.94M | 5M | (13M) | (19.82M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 45.01M |
| Common Stock Repurchased | 0 | (194K) | (78K) | (176K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (22K) | 797K | 1.64M | (439K) | (190.27K) |
| Financing Cash Flow | 4.98M | 20.73M | 6.64M | (13.62M) | 25.01M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (1.5M) |
| Net Change in Cash | (9.24M) | 2.67M | (10.51M) | 13.37M | 8.83M |
| Free Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (14.67M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$9.7M
+ D&A$103.0K
+ Stock-Based Comp$7.0M
+ Deferred Tax$0
- Working Capital-$12.0M
- Other Non-Cash-$26.4K
= Operating Cash Flow-$14.7M
- Capex$0
= Free Cash Flow-$14.7M
Analysis
FY2025 free cash flow is -$14.7M. FCF conversion is 150.6% of net income. Operating cash flow was -$14.7M, with capex of $0. The largest bridge item is Working Capital at -$12.0M.
Recent Filings
Recent regulatory filings
No filings found.
Does FRX.TO generate free cash flow?
Fennec Pharmaceuticals Inc. (FRX.TO) generated -$14.67M of free cash flow in fiscal 2025.
How much operating cash flow does FRX.TO produce?
Operating cash flow was -$14.67M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.